CALGARY, AB – February 27, 2018 – XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE:XRX),
a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney
disease, is pleased to provide this corporate update.

“With the successful close of the Company’s recent merger with APAC Resources Inc. and the fund raise
associated with that transaction, XORTX is continuing its efforts to strengthen the XORTX team and has
made good advancements on the preparation of documents for review by the FDA for upcoming phase II
trials as well as identifying additional strategic programs to drive revenue and bolster value of XORTX,”
stated Dr. Allen Davidoff, CEO.

XORTX Operations – These past couple of months has seen significant progress in the preparation of
documents for review by the FDA for the Company’s upcoming phase II trials associated with XORTX’s
lead programs to develop treatments for progressive kidney disease due to diabetes, diabetic nephropathy
and polycystic kidney disease. XORTX continues to be encouraged by the number of studies and work
being reported that validate the Company’s focus, patent portfolio and the importance of addressing this
unmet medical need in progressive kidney disease. Notable recent publications on the need for XORTX’s
drug advancement include:

https://www.renalandurologynews.com/hyperuricemia/chronic-kidney-diseasehyperuricemia-trajectories-esrd-mortality-tied/article/742944/

and,

http://www.renalandurologynews.com/hyperuricemia/ckd-hyperuricemia-uric-acid-lowering-treatment-helpskidney-disease-cv-events/article/707042/.

XORTX Team – XORTX continues to build its team with key corporate appointments including two new
board members and a new Chief Financial Officer. New board members Paul Van Damme, who has a
strong biopharmaceutical and finance background to head up the Company’s audit committee and Allan
Williams, an independent businessman with strong ties to the financial community to assist XORTX with its
capital raising needs going forward join XORTX founder Dr. Allen Davidoff and long time director Bruce
Rowlands on the Company’s board of directors. XORTX has also strengthened its management team with
David Matthews being appointed Chief Financial Officer. See press releases of January 29th and February
22nd.

About XORTX Therapeutics Inc.

XORTX Therapeutics Inc. is a BioPharmaceutical company focused on developing innovative therapies to
treat progressive kidney disease. XORTX has lead programs to develop treatments for progressive kidney
disease due to diabetes, diabetic nephropathy and polycystic kidney disease. Secondary programs focus
on developing therapies for health consequences that accompany pre-diabetes, diabetes and
cardiovascular disease. Additional information on XORTX Therapeutics is available at www.XORTX.com.

For further information, please contact: Erik Matthews, Corporate Communications & Investor Relations
+1-747-203-5240 or erik@xortx.com / ray@xortx.com

The CSE has neither approved nor disapproved the contents of this news release. No stock exchange,
securities commission or other regulatory authority has approved or disapproved the information contained
herein.